SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a broad pipeline of protein-based pharmaceutical and non-pharmaceutical products, today announced management’s nominations for election to its Board of Directors at its upcoming Annual Shareholders’ Meeting. In addition to the current seven board members, the slate includes Hartley T. Richardson, who recently agreed to be nominated and currently serves as
President and Chief Executive Officer of James Richardson & Sons, Limited.

“The leadership and success demonstrated by our directors has set the example for our entire organization. The addition of Mr. Richardson would add to both the strength of our Board and the strategic direction of SemBioSys through his experience in business and agriculture from James Richardson & Sons, a leader in Canadian agriculture for nearly 150 years,” said Andrew Baum, President and CEO, SemBioSys.

The Company's Annual Shareholders’ Meeting will be held at 2:00 p.m. (Calgary time) on Tuesday, May 3, 2005 at the Company’s corporate headquarters #110, 2985 - 23rd Avenue N.E. Calgary, Alberta. Information pertaining to the nomination of Directors and other business matters will be mailed out in the coming weeks as part of the materials for the meeting.

Complete list of nominations (alphabetical order):

• Andrew Baum, President and CEO of SemBioSys Genetics Inc.

• Paul Cataford, President and CEO of University Technologies International Inc.

• David Cox, President and CEO of Altachem Pharma Ltd.

• Douglass B. Given, Partner at Bay City Capital

• Nancy Harrison, Senior Vice President of Ventures West Management Inc.

• David Howard, Chairperson of Angiotech Pharmaceuticals, Inc.

• Hartley T. Richardson, President and CEO of James Richardson & Sons, Limited

• Richard Smith, President and CEO of Dow AgroSciences Canada, Inc.

Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company focused on the development, commercialization and production of protein-based pharmaceuticals and nonpharmaceutical products based on its plant genetic engineering skills and proprietary oilbody-oleosin technology platform - the Stratosome™ Biologics System. Its two lead pharmaceutical products are insulin and a developmental cardiovascular drug called Apo AI. It also has a series of nonpharmaceutical products addressing animal health, industrial and human topical markets. SemBioSys currently has five major funded partnership agreements with Syngenta Participations
AG, Martek Biosciences Corporation, Lonza, Inc., Dow AgroSciences LLC and Arcadia Biosciences, Inc.